Zanubrutinib - Share Your Cancer Stories | Cancer News & Awareness Updates

Browsing: Zanubrutinib

Diagnosis

Long-Term Efficacy Data on Zanubrutinib from SEQUOIA

By NewsCancerJuly 14, 20260

Dr. Lipsky reviews the ELEVATE-TN trial supporting acalabrutinib approval in frontline CLL, demonstrating superiority over chlorambucil-obinutuzumab. He notes a potential…

Survivors

Rationale for Pairing Sonrotoclax With Zanubrutinib in Relapsed or Refractory CLL

By NewsCancerJune 30, 20260

Dr. Mazyar Shadman discusses the scientific rationale for combining sonrotoclax with zanubrutinib for the treatment of patients with relapsed or…

Support

Sonrotoclax Plus Zanubrutinib Achieves >90% uMRD in Treatment-Naive CLL/SLL

By NewsCancerJune 14, 20260

The all-oral combination of sonrotoclax (BGB-11417) and zanubrutinib (Brukinsa) produced undetectable minimal residual disease (uMRD) rates exceeding 90% in patients…

Support

Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings

By NewsCancerMay 1, 20260

In a Between the Lines program, 2 hematologic oncology specialists, Ian Flinn, MD, PhD, and Danielle Brander, MD, discussed biomarker…

Survivors

Practical Considerations for Integrating Zanubrutinib Plus Venetoclax in CLL Therapy

By NewsCancerFebruary 21, 20260

In this segment, Drs. Brander and Flinn discuss the potential integration of the zanubrutinib and venetoclax combination into clinical practice…

Survivors

ALPINE Lont-Term Follow-Up: Zanubrutinib, Venetoclax Combinations, and Long-Term Outcomes

By NewsCancerFebruary 20, 20260

In this discussion, Drs. Flinn and Brander review recent advances in CLL therapy, focusing on BTK inhibitors, venetoclax, and combination…

What's Hot

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma

Browsing: Zanubrutinib

Long-Term Efficacy Data on Zanubrutinib from SEQUOIA

Rationale for Pairing Sonrotoclax With Zanubrutinib in Relapsed or Refractory CLL

Sonrotoclax Plus Zanubrutinib Achieves >90% uMRD in Treatment-Naive CLL/SLL

Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings

Practical Considerations for Integrating Zanubrutinib Plus Venetoclax in CLL Therapy

ALPINE Lont-Term Follow-Up: Zanubrutinib, Venetoclax Combinations, and Long-Term Outcomes

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma

ATR inhibition induces NF-κB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma

ATR inhibition induces NF-κB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING

Latest Post

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma

Subscribe to Updates

What's Hot

Browsing: Zanubrutinib